Japan approves AstraZeneca’s Forxiga to treat chronic kidney disease in patients with and without type-2 diabetes, Health News, ET HealthWorld
United Kingdom : AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without…
